Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor

SIMPLE SUMMARY: Imatinib mesylate (IM, Gleevec) has remained first-line therapy for most gastrointestinal stromal tumor (GIST) patients since 2002. During this time, three additional inhibitors have been approved for treatment of IM-refractory tumors; however, disease stabilization for these agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozinova, Marya, Joshi, Shalina, Ye, Shuai, Belinsky, Martin G., Sharipova, Dinara, Farma, Jeffrey M., Reddy, Sanjay S., Litwin, Samuel, Devarajan, Karthik, Campos, Alex Rosa, Yu, Yi, Schwartz, Brian, von Mehren, Margaret, Rink, Lori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345102/
https://www.ncbi.nlm.nih.gov/pubmed/34359600
http://dx.doi.org/10.3390/cancers13153699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345102/
https://www.ncbi.nlm.nih.gov/pubmed/34359600
http://dx.doi.org/10.3390/cancers13153699

Ejemplares similares